Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer

eLife

Volumn 6, Issue , 2017, Pages

  Li, Jianneng ^a   Alyamani, Mohammad ^a,b   Zhang, Ao ^a   Chang, Kai Hsiung ^a   Berk, Michael ^a   Li, Zhenfei ^a   Zhu, Ziqi ^a   Petro, Marianne ^a   Magi Galluzzi, Cristina ^c   Taplin, Mary Ellen ^d   Garcia, Jorge A ^e   Courtney, Kevin ^f   Klein, Eric A ^g   Sharifi, Nima ^a,b,e,g  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND STATE UNIVERSITY   (United States)

^c Pathology and Laboratory Medicine Institute   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Taussig Cancer Institute   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g Glickman Urological and Kidney Institute ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CORTICOSTEROID; ENZALUTAMIDE; GLUCOCORTICOID; UBIQUITIN; ANTINEOPLASTIC AGENT; GLUCOCORTICOID RECEPTOR; PHENYLTHIOHYDANTOIN;

ARTICLE; CELL VIABILITY ASSAY; ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROCORTISONE BLOOD LEVEL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; ORCHIECTOMY; POLYMERASE CHAIN REACTION; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; UBIQUITINATION; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; DRUG RESISTANCE; HUMAN; METABOLISM; PROSTATE TUMOR; XENOGRAFT;

ADRENAL CORTEX HORMONES; ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; HETEROGRAFTS; HUMANS; MALE; MICE; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS; RECEPTORS, GLUCOCORTICOID;

EID: 85013498415     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.20183     Document Type: Article

References (28)

1. Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zheng D, Sawyers CL. 2013. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155:1309-1322. doi: 10.1016/j.cell.2013.11.012, PMID: 24315100
2. Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I, Drake CG, de Bono JS. 2016. Prostate cancer. The Lancet 387:70-82. doi: 10.1016/S0140-6736(14)61947-4
3. Attard G, Reid AH, Auchus RJ, Hughes BA, Cassidy AM, Thompson E, Oommen NB, Folkerd E, Dowsett M, Arlt W, de Bono JS. 2012. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. The Journal of Clinical Endocrinology & Metabolism 97:507-516. doi: 10.1210/jc.2011-2189, PMID: 22170708
4. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, et al. 2014. Enzalutamide in metastatic prostate cancer before chemotherapy. New England Journal of Medicine 371:424-433. doi: 10.1056/NEJMoa1405095, PMID: 24881730
5. Browman DT, Resek ME, Zajchowski LD, Robbins SM. 2006. Erlin-1 and erlin-2 are novel members of the prohibitin family of proteins that define lipid-raft-like domains of the ER. Journal of Cell Science 119:3149-3160. doi: 10.1242/jcs.03060, PMID: 16835267
6. Chang K-H, Li R, Papari-Zareei M, Watumull L, Zhao YD, Auchus RJ, Sharifi N. 2011. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. PNAS 108:13728-13733. doi: 10.1073/pnas.1107898108, PMID: 21795608
7. Chang KH, Li R, Kuri B, Lotan Y, Roehrborn CG, Liu J, Vessella R, Nelson PS, Kapur P, Guo X, Mirzaei H, Auchus RJ, Sharifi N. 2013. A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell 154:1074-1084. doi: 10.1016/j.cell.2013.07.029, PMID: 23993097
8. Chapman K, Holmes M, Seckl J. 2013. 11b-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action. Physiological Reviews 93:1139-1206. doi: 10.1152/physrev.00020.2012, PMID: 23899562
9. Efstathiou E, Li W, Gormley M. 2015. Biological heterogeneity in localized high-risk prostate cancer (LHRPC) from a study of neoadjuvant abiraterone acetate plus leuprolide acetate (LHRHa) versus LHRHa. 2015 ASCO Annual Meeting.
10. Hearn JW, AbuAli G, Reichard CA, Reddy CA, Magi-Galluzzi C, Chang KH, Carlson R, Rangel L, Reagan K, Davis BJ, Karnes RJ, Kohli M, Tindall D, Klein EA, Sharifi N. 2016. HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. The Lancet Oncology 17:1435-1444. doi: 10.1016/S1470-2045(16)30227-3, PMID: 27575027
11. Huber MD, Vesely PW, Datta K, Gerace L. 2013. Erlins restrict SREBP activation in the ER and regulate cellular cholesterol homeostasis. The Journal of Cell Biology 203:427-436. doi: 10.1083/jcb.201305076, PMID: 24217618
12. Isikbay M, Otto K, Kregel S, Kach J, Cai Y, Vander Griend DJ, Conzen SD, Szmulewitz RZ. 2014. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Hormones and Cancer 5:72-89. doi: 10.1007/s12672-014-0173-2, PMID: 24615402
13. Jeanneteau F, Garabedian MJ, Chao MV. 2008. Activation of Trk neurotrophin receptors by glucocorticoids provides a neuroprotective effect. PNAS 105:4862-4867. doi: 10.1073/pnas.0709102105, PMID: 18347336
14. Kach J, Conzen SD, Szmulewitz RZ. 2015. Targeting the glucocorticoid receptor in breast and prostate cancers. Science Translational Medicine 7:305ps19. doi: 10.1126/scitranslmed.aac7531, PMID: 26378243
15. Knudsen KE, Penning TM. 2010.Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends in Endocrinology & Metabolism 21:315-324. doi: 10.1016/j.tem.2010.01.002, PMID: 20138542
16. Li J, Wang W, Liu C, Wang W, Li W, Shu Q, Chen ZJ, Sun K. 2013. Critical role of histone acetylation by p300 in human placental 11b-HSD2 expression. The Journal of Clinical Endocrinology & Metabolism 98:E1189-E1197. doi: 10.1210/jc.2012-4291, PMID: 23714681
17. Li Z, Bishop AC, Alyamani M, Garcia JA, Dreicer R, Bunch D, Liu J, Upadhyay SK, Auchus RJ, Sharifi N. 2015. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature 523:347-351. doi: 10.1038/nature14406, PMID: 26030522
18. Miller WL, Auchus RJ. 2011. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocrine Reviews 32:81-151. doi: 10.1210/er.2010-0013, PMID: 21051590
19. Montgomery B, Cheng HH, Drechsler J, Mostaghel EA. 2014. Glucocorticoids and prostate cancer treatment: friend or foe? Asian Journal of Andrology 16:354-358. doi: 10.4103/1008-682X.125392, PMID: 24625881
20. Mostaghel EA, Plymate SR, Montgomery B. 2014. Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit. Clinical Cancer Research 20:791-798. doi: 10.1158/1078-0432.CCR-12-3601, PMID: 24305618
21. Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, Rimm DL, Liu XS, Brown M. 2011. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 20:119-131. doi: 10.1016/j.ccr.2011.05.026, PMID: 21741601
22. Pearce MM, Wang Y, Kelley GG, Wojcikiewicz RJ. 2007. SPFH2 mediates the endoplasmic reticulum-associated degradation of inositol 1,4,5-trisphosphate receptors and other substrates in mammalian cells. Journal of Biological Chemistry 282:20104-20115. doi: 10.1074/jbc.M701862200, PMID: 17502376
23. Sartor O, Parker CC, de Bono J. 2014. Reappraisal of glucocorticoids in castrate-resistant prostate cancer. Asian Journal of Andrology 16:666. doi: 10.4103/1008-682X.133314, PMID: 24994787
24. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS, AFFIRM Investigators. 2012. Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England Journal of Medicine 367:1187-1197. doi: 10.1056/NEJMoa1207506, PMID: 22894553
25. Scher HI, Sawyers CL. 2005. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. Journal of Clinical Oncology 23:8253-8261. doi: 10.1200/JCO. 2005.03.4777, PMID: 16278481
26. Sharifi N. 2013. Minireview: Androgen metabolism in castration-resistant prostate cancer. Molecular Endocrinology 27:708-714. doi: 10.1210/me.2013-1007, PMID: 23592429
27. Sharifi N. 2014. Steroid receptors aplenty in prostate cancer. The New England Journal of Medicine 370:970-971. doi: 10.1056/NEJMcibr1315706, PMID: 24597872
28. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL. 2009. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324: 787-790. doi: 10.1126/science.1168175, PMID: 19359544